(2R,3R,4R,5S)-6-Cyclohexyl-3,4-dihydroxy-5-{(S)-3-(1H-imidazol-4-yl)-2-[2-(naphthalen-1-yloxy)-acetylamino]-propionylamino}-2-isopropyl-hexanoic acid {(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butyl}-amide | 112190-24-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (2R,3R,4R,5S)-6-Cyclohexyl-3,4-dihydroxy-5-{(S)-3-(1H-imidazol-4-yl)-2-[2-(naphthalen-1-yloxy)-acetylamino]-propionylamino}-2-isopropyl-hexanoic acid {(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butyl}-amide
• 英文别名: (2R,3R,4R,5S)-6-cyclohexyl-3,4-dihydroxy-5-[[(2S)-3-(1H-imidazol-5-yl)-2-[(2-naphthalen-1-yloxyacetyl)amino]propanoyl]amino]-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]-2-propan-2-ylhexanamide
• CAS: 112190-24-6
• 化学式: C₄₅H₆₁N₇O₇
• 分子量: 812.022
• InChiKey: ZTKCGLWIXHAITR-JIFWBGJESA-N

物化性质

• 沸点：
  1158.5±65.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  59
• 可旋转键数：
  21
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  208
• 氢给体数：
  7
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2(R)-<5(R)-<1(S)-<(tert-butyloxycarbonyl)amino>-2-cyclohexylethyl>-2,2-dimethyl-4(R)-dioxolanyl>-3-methylbutanoic acid 在 ethandithiol 、 diethylphosphoryl cyanide 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 乙酰氯 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 33.25h， 生成 (2R,3R,4R,5S)-6-Cyclohexyl-3,4-dihydroxy-5-{(S)-3-(1H-imidazol-4-yl)-2-[2-(naphthalen-1-yloxy)-acetylamino]-propionylamino}-2-isopropyl-hexanoic acid {(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butyl}-amide
  参考文献：
  名称：

  Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity

  摘要：

  The peptidomimetic template and the dihydroxyethylene isostere insert that were applied successfully to the design of renin inhibitors have been extended to the related protease from human immunodeficiency virus (HIV). The present report describes the structure-activity study leading to the identification of an inhibitor with a K(i) of < 1 nM for the HIV type-1 protease (compound II). This compound, containing a diol insert, is highly effective in blocking polyprotein processing in in vitro cell culture assays. Results obtained from kinetic analysis, studies of the stereochemistry of the insert, and modeling have led to insights as to the requisites involved in the active site-inhibitor interaction.

  DOI：

  10.1021/jm00112a005

文献信息

• USE OF COMPOUNDS FOR THE TREATMENT OF PAIN
  申请人：Akron Molecules AG

  公开号：EP2846788A1

  公开（公告）日：2015-03-18
• [EN] USE OF COMPOUNDS FOR THE TREATMENT OF PAIN<br/>[FR] UTILISATION DE COMPOSÉS POUR LE TRAITEMENT DE LA DOULEUR
  申请人：AKRON MOLECULES GMBH

  公开号：WO2013167743A1

  公开（公告）日：2013-11-14

  The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.
• Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity
  作者：Suvit Thaisrivongs、Alfredo G. Tomasselli、Joseph B. Moon、John Hui、Thomas J. McQuade、Steve R. Turner、Joseph W. Strohbach、W. Jeffrey Howe、W. Gary Tarpley、Robert L. Heinrikson

  DOI：10.1021/jm00112a005

  日期：1991.8

  The peptidomimetic template and the dihydroxyethylene isostere insert that were applied successfully to the design of renin inhibitors have been extended to the related protease from human immunodeficiency virus (HIV). The present report describes the structure-activity study leading to the identification of an inhibitor with a K(i) of < 1 nM for the HIV type-1 protease (compound II). This compound, containing a diol insert, is highly effective in blocking polyprotein processing in in vitro cell culture assays. Results obtained from kinetic analysis, studies of the stereochemistry of the insert, and modeling have led to insights as to the requisites involved in the active site-inhibitor interaction.